Nyman U, Almén T, Aspelin P, Hellström M, Kristiansson M, Sterner Gunnar
Department of Radiology, Lasarettet Trelleborg, Trelleborg, Sweden.
Acta Radiol. 2005 Dec;46(8):830-42. doi: 10.1080/02841850500335051.
To suggest a more precise tool when assessing the risk of contrast-medium-induced nephropathy (CIN), i.e. the ratio between contrast medium (CM) dose expressed in grams of iodine (g-I) and estimated glomerular filtration rate in ml/min (eGFR; based on equations using serum-creatinine (s-Cr), weight, height, age, and/or sex), here named I-dose/GFR ratio.
A Medline search of published CIN investigations reporting mean eGFR and mean dose of low-osmolality CM (LOCM) identified 10 randomized controlled prophylactic and 2 cohort coronary investigations, and 3 randomized and 1 cohort computed tomographic (CT) investigation. From the randomized trials, data were collected only from the placebo or control arms, unless there was no significant difference between the control and test groups. The mean I-dose/GFR ratio of each study was correlated with the mean frequency of CIN-1 (s-Cr rise> or =44.2 micromol/l or > or =20-25%) and CIN-2 (oliguria or requiring dialysis). A maximum dose according to an I-dose/GFR ratio= 1 in patients with s-Cr ranging from 100 to 300 micromol/l was compared with that of CIGARROA'S formula and with a "European consensus" threshold published by the European Society of Urogenital Radiology, both using s-Cr alone to predict renal function. McCullough's formula was used to assess the risk of CIN requiring dialysis at an I-dose/GFR ratio= 1 with LOCM.
The coronary investigations revealed a linear correlation with a correlation coefficient between the I-dose/GFR ratio and the frequency of CIN-1 and CIN-2 of 0.91 (P<0.001) and 0.84 (P=0.001), respectively. At a mean I-dose/GFR ratio= 1, the regression line indicated a 10%) risk of CIN-1 and a 1% risk of CIN-2. At a mean I-dose/ GFR ratio=3, the risk of CIN-1 and CIN-2 increased to about 50% and 15%, respectively. Pooled weighted data from the CT investigations revealed a 12% risk of CIN-1 at a mean I-dose/GFR ratio = 1.1 and no cases of CIN-2. The maximum CM dose according to an I-dose/GFR ratio= 1 was about 30-50% of that of both Cigarroa's formula and the "European consensus" in elderly low-weight individuals, while it was similar for middle-aged individuals weighing about 90 kg. McCullough's formula suggests that there will be an exponentially increasing risk of CIN requiring dialysis, but at an I-dose/GFR ratio= 1 and using LOCM it will not exceed 1% until GFR decreases below 30 ml/min in diabetics and below 20 ml/min in non-diabetics.
Using the I-dose/GFR ratio may be a more expedient way of improving risk assessment of CIN than today's common practice of estimating CM dose from volume alone and renal function from s-Cr alone. Prospective studies based on individual patient data are encouraged to define the risk of CIN at various I-dose/GFR ratios and correlated to type of CM, examination, risk factors, etc.
提出一种在评估造影剂诱发肾病(CIN)风险时更为精确的工具,即碘克数(g-I)表示的造影剂(CM)剂量与以毫升/分钟为单位的估算肾小球滤过率(eGFR;基于使用血清肌酐(s-Cr)、体重、身高、年龄和/或性别的公式)之间的比值,此处命名为碘剂量/肾小球滤过率比值。
对已发表的关于CIN的研究进行Medline检索,这些研究报告了低渗造影剂(LOCM)的平均eGFR和平均剂量,共确定了10项随机对照预防性和2项队列冠状动脉研究,以及3项随机和1项队列计算机断层扫描(CT)研究。从随机试验中,仅收集安慰剂或对照组的数据,除非对照组与试验组之间无显著差异。将每项研究的平均碘剂量/肾小球滤过率比值与CIN-1(s-Cr升高≥44.2微摩尔/升或≥20 - 25%)和CIN-2(少尿或需要透析)的平均发生率相关联。将s-Cr范围为100至300微摩尔/升的患者中碘剂量/肾小球滤过率比值 = 1时的最大剂量与CIGARROA公式以及欧洲泌尿生殖放射学会公布的“欧洲共识”阈值进行比较,两者均仅使用s-Cr来预测肾功能。使用McCullough公式评估碘剂量/肾小球滤过率比值 = 1且使用LOCM时需要透析的CIN风险。
冠状动脉研究显示碘剂量/肾小球滤过率比值与CIN-1和CIN-2发生率之间呈线性相关,相关系数分别为0.91(P < 0.001)和0.84(P = 0.001)。在平均碘剂量/肾小球滤过率比值 = 1时,回归线表明CIN-1的风险为10%,CIN-2的风险为1%。在平均碘剂量/肾小球滤过率比值 = 3时,CIN-1和CIN-2的风险分别增加至约50%和15%。CT研究的汇总加权数据显示,在平均碘剂量/肾小球滤过率比值 = 1.1时,CIN-1的风险为12%,无CIN-2病例。在老年低体重个体中,碘剂量/肾小球滤过率比值 = 1时的最大CM剂量约为Cigarroa公式和“欧洲共识”剂量的30 - 50%,而对于体重约90公斤的中年个体则相似。McCullough公式表明需要透析的CIN风险将呈指数增加,但在碘剂量/肾小球滤过率比值 = 1且使用LOCM时,直到糖尿病患者的GFR降至低于30毫升/分钟且非糖尿病患者的GFR降至低于20毫升/分钟时,该风险才会超过1%。
与目前仅根据体积估算CM剂量且仅根据s-Cr估算肾功能的常见做法相比,使用碘剂量/肾小球滤过率比值可能是一种更便捷的改善CIN风险评估方法。鼓励基于个体患者数据的前瞻性研究来确定不同碘剂量/肾小球滤过率比值下CIN的风险,并将其与CM类型、检查、风险因素等相关联。